Istituto Europeo Di Oncologia S.r.l.

At Istituto Europeo Di Oncologia S.r.l. in Milan, a major share of the clinical research focuses on breast cancer and gynecologic cancers, especially ovarian cancer, endometrial cancer, and cervical cancer. These studies are designed to test new treatment approaches, refine adjuvant and neoadjuvant strategies, and improve outcomes for patients with early-stage, advanced, and recurrent disease.

• New therapies for HER2-positive, HR-positive, and triple-negative breast cancer
• Treatment research in ovarian, endometrial, and cervical malignancies
• Studies assessing whether adding targeted or immune-based treatments can improve disease control

This area also includes work on diagnostic imaging and response evaluation, helping clinicians better identify disease and tailor treatment for women with complex cancers.

A large part of the trial portfolio centers on lung cancer, including non-small cell lung cancer and small cell lung cancer, with a strong emphasis on biomarker-defined disease such as EGFR, ALK, ROS1, KRAS G12C, and HER2 alterations. The research aims to improve treatment effectiveness, especially for advanced or metastatic disease, and to identify more precise options for patients whose cancer has returned or progressed.

• Targeted treatment studies for molecularly selected NSCLC
• Immunotherapy-based approaches for advanced thoracic cancers
• Trials exploring better control of recurrent, metastatic, and treatment-resistant disease

The site’s thoracic oncology program reflects a strong focus on matching the right therapy to the right tumor profile, with research spanning both early and advanced stages of disease.

Research in female urogenital diseases is especially active, with many trials in ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and endometrial carcinoma. These studies commonly aim to improve treatment for platinum-resistant or recurrent disease, while also exploring ways to extend remission and reduce the risk of relapse.

• New treatment options for advanced ovarian cancer and related gynecologic tumors
• Studies for recurrent and metastatic endometrial cancer
• Trials focused on improving outcomes after standard therapy has stopped working

This research area supports a broader effort at the Gynecology Oncology Department to bring more personalized care to women with difficult-to-treat cancers.

The site also conducts substantial research in prostate cancer, bladder cancer, urothelial carcinoma, and renal cell carcinoma. These trials are aimed at improving treatment response in advanced or metastatic disease, especially where standard options have become less effective.

• Therapy research for metastatic castration-resistant prostate cancer
• Studies in urothelial and muscle-invasive bladder cancer
• Trials in renal cell carcinoma exploring better disease control after prior treatment

Several studies in this field are testing whether targeted or immune-based treatments can offer better disease control and longer-lasting benefit for patients with advanced genitourinary cancers.

A notable portion of the research portfolio addresses blood cancers, including acute myeloid leukemia, lymphoma, multiple myeloma, and myelofibrosis. These trials are designed to evaluate new treatment combinations, improve outcomes after relapse, and support patients whose disease has returned after previous therapy.

• Research in diffuse large B-cell lymphoma and other aggressive lymphomas
• Studies for relapsed or refractory multiple myeloma
• Trials exploring better post-transplant or maintenance strategies in leukemia

The focus on hematology complements the site’s broader oncology expertise, with research aimed at both improving survival and finding more tolerable treatment options.

Across many tumor types, the site runs trials in immunotherapy, targeted therapy, and other forms of precision oncology. These studies span melanoma, head and neck cancer, gastrointestinal cancers, and other advanced solid tumors, with the goal of improving response rates and extending survival.

• Combination studies testing whether adding immune-based treatment improves cancer control
• Targeted therapy research for tumors with specific genetic changes
• Trials in advanced solid tumors where standard treatments are limited or no longer effective

This broad research stream reflects the site’s strong interest in matching treatment to tumor biology and in developing more effective options for patients with hard-to-treat cancers.

Beyond treatment trials, the Istituto Europeo di Oncologia S.r.l. also contributes to research in diagnostics, imaging, and health care evaluation. These studies aim to improve early detection, better assess treatment response, and refine the overall quality of cancer care.

• Studies evaluating new or improved diagnostic techniques
• Research on imaging methods to support more accurate cancer assessment
• Trials focused on patient-centered care and treatment experience

This work adds an important practical dimension to the site’s oncology program by supporting earlier diagnosis and more informed treatment decisions.